

Please try another search
By Scott Kanowsky
Investing.com -- Sanofi SA (EPA:SASY) agreed to purchase US-based pharmaceutical firm Provention Bio (NASDAQ:PRVB) in a deal worth approximately $2.9 billion, as the French drugmaker looks to boost its general medicines portfolio with a US-approved type 1 diabetes drug.
In a statement, Sanofi said the deal, which is expected to close in the second quarter of 2023, will give it full ownership of TZIELD, a treatment used to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 and older.
The move also helps address recent investor criticism over Sanofi's pipeline of drugs, although growth in the company's asthma and eczema medicines has remained strong.
Sanofi executive vice president Olivier Charmeil said the agreement, which will see it buy Provention Bio for $25 per share, builds on a previous partnership between the two groups.
"By coupling Provention Bio’s transformative innovation with Sanofi's expertise, we aim to bring life-changing benefits to people at risk of developing Stage 3 type 1 diabetes. Any additional indications, approvals and pipeline assets only serve to further our excitement," Charmeil added.
Provention stock jumped by more than 258% following the announcement, while Paris-listed shares in Sanofi edged lower.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.